文献速递甲状腺核医学核素与放射性配体治疗放射性药物与辐射防护

分化型甲状腺癌放射性碘治疗后继发癌症的发生率及相关因素:一项多中心回顾性研究

Incidence rate and factors associated with the development of secondary cancers after radioiodine therapy in differentiated thyroid cancer: a multicenter retrospective study.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2021-11-13

该多中心回顾性研究纳入2000年1月1日至2005年12月31日在韩国七家三级医院因分化型甲状腺癌行全甲状腺切除术后首次接受放射性碘治疗的3106例患者,随访11.9±4.6年,发生继发癌症173例(5.6%),血液系统癌症和总癌症发生率显著高于韩国一般人群,实体癌发生率无显著差异;多因素分析显示首次放射性碘治疗时年龄、男性、总累积剂量超过200 mCi为继发癌症的独立预后因素。

要点

  • 3106例分化型甲状腺癌患者放射性碘治疗后继发癌症173例(5.6%),含实体癌162例、血液系统癌症21例。
  • 实体癌发生率与韩国一般人群无显著差异,血液系统癌症和总癌症发生率显著高于韩国一般人群。
  • 首次放射性碘治疗时年龄、男性、总累积剂量超过200 mCi为继发癌症的独立预后因素。

核心结论

  • 放射性碘治疗后实体癌发生率与韩国一般人群无显著差异,但血液系统癌症和总癌症发生率显著高于韩国一般人群。
  • 首次放射性碘治疗时年龄、男性、总累积剂量超过200 mCi为继发癌症的独立预后因素。
  • 作者认为需要评估总累积剂量超过200 mCi患者的风险获益。

研究设计与样本

  • 多中心回顾性研究,从韩国七家三级医院收集2000年1月1日至2005年12月31日因分化型甲状腺癌行全甲状腺切除术后首次接受放射性碘治疗患者的病历。
  • 共纳入3106例患者,诊断甲状腺癌时平均年龄45.7±13.3岁,女性2669例(85.9%)。
  • 随访期11.9±4.6年(范围1.2-19.6年)。
  • 将癌症发生率及计算的标准率比与韩国癌症发病数据比较,采用Cox比例风险回归分析继发癌症与各参数的关系。

主要发现

  • 173例患者(5.6%)发生183例继发癌症,包括162例实体癌和21例血液系统癌症。
  • 接受放射性碘治疗的研究人群实体癌发生率与韩国一般人群无显著差异。
  • 研究人群中血液系统癌症和总癌症发生率显著高于韩国一般人群。
  • 多因素分析确定继发癌症的独立预后因素包括首次放射性碘治疗时年龄、男性、总累积剂量超过200 mCi。

临床怎么用

  • 作者认为需要评估接受总累积剂量超过200 mCi患者的风险获益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The objective of this study was to estimate the incidence of secondary cancers and the factors associated with their development among patients who underwent radioiodine therapy (RIT) with differentiated thyroid cancer. METHODS: We retrospectively collected medical records for patients who underwent first RIT between January 1, 2000, and December 31, 2005, from seven tertiary hospitals in South Korea after total thyroidectomy for differentiated thyroid cancer. Cancer incidence and calculated standardized rate ratio were compared with Korean cancer incidence data. The association between the development of secondary cancers and various parameters was analyzed by Cox-proportional hazard regression. RESULTS: A total of 3106 patients were included in this study. Mean age at the time of diagnosis of thyroid cancer was 45.7 ± 13.3 years old, and 2669 (85.9%) patients were female. The follow-up period was 11.9 ± 4.6 (range, 1.2-19.6) years. A total of 183 secondary cancers, which included 162 solid and 21 hematologic cancers, occurred in 173 patients (5.6%). There was no significant difference between solid cancer incidence in our study population who underwent RIT and the overall Korean population, but the incidence of hematologic cancers and total cancer in our study was significantly higher compared with that of the Korean population. A multivariate analysis identified independent prognostic factors for the development of secondary cancer including age at 1st RIT, male, and total cumulative dose over 200 mCi. CONCLUSION: We need to assess the risk benefit for patients who receive over 200 mCi of a total cumulative dose.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Hong CM, Shin JY, Kim BI, et al. Incidence rate and factors associated with the development of secondary cancers after radioiodine therapy in differentiated thyroid cancer: a multicenter retrospective study. Eur J Nucl Med Mol Imaging. 2021. PMID: 34773164. doi:10.1007/s00259-021-05608-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。